Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Investor Presentation (March 2017)
11 slides from Aft Pharmaceuticals's investor presentation, Mar 17, 2017
Slide 1: AFT Pharmaceuticals Business Update and Redeemable Share Issue
For personal use only AFT PHARMACEUTICALS Business Update and Redeemable Share Issue 17 March 2017
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT to selected recipients in New Zealand. It is not prepared for any other purpose and must not be reproduced or provided to any person other than the intended recipient. It
Slide 3: Progress Update
PROGRESS UPDATE Countries that Maxigesic is licensed in – up from 98 at the end of 111 FY2016. Negotiations underway for North America (MX & US/CA to follow) & EU For personal use only 6 Countries that Maxigesic has launched and is sold in with at least 20 further launches expected during this calen
Slide 4: Maxigesic Update
MAXIGESIC UPDATE Eastern Europe – launched in UK – successfully launched 2017 and pending Italy – successful launch and Nordics – launches in 2017 sales increasing significantly For personal use only Kuwait launch pending soon UAE – sales doubling in second year of sales Malaysia – launch in 2017 Si
Slide 5: Maxigesic Sales Progress to Date
MAXIGESIC SALES PROGRESS TO DATE Maxigesic Tablets Sold Per Year For personal use only 80 Millions 60 40 20 - FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017* • Maxigesic tablet sales for the FY2017 financial year are expected to increase to 74 million tablets per annum, representing a 339%
Slide 6: NasoSURF Nebuliser: Drug Delivery and Treatment of Sinus Conditions
NASOSURF NEBULISER DRUG DELIVERY AND TREATMENT OF SINUS CONDITIONS For personal use only A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of chronic description sinusitis • To expand our existing allergy and hospital product ranges The NasoSU
Slide 7: Other Key Innovative Products
OTHER KEY INNOVATIVE PRODUCTS Products Status For personal use only Pascomer currently being developed, with an IND Application to be opened in US during 2017 to enable the pivotal clinical study to be undertaken Successfully obtained ODD from FDA. EMA under application after successful meeting FDA
Slide 8: R&D / Marketing Expenditure Since IPO
For personal use only R&D / MARKETING EXPENDITURE SINCE IPO As expected at time Spend to Mar ‘18 Purpose Spent to Dec ‘16 of IPO (Dec 2015) (15 months) Product Development - Maxigesic $13.2m $4.7m $8.0m - NasoS urf $2.9m $1.1m $1.1m - Maxiclear $1.5m $0.3m $0.2m - Fibroleve $0.4m $0.3m completed - C
Slide 9: Funding
FUNDING Redeemable Shares For personal use only • In order to provide additional balance sheet capacity enabling AFT to pursue its planned R&D programme, AFT is undertaking a capital raise involving an issue of redeemable shares • CRG is participating for approximately NZ$7.1m of redeemable shares •
Slide 10: Redeemable Share Issue – Key Terms
REDEEMABLE SHARE ISSUE – KEY TERMS The volume weighted average price of AFT’s ordinary shares on the NZX over the five business days prior Issue Price to the announcement of the redeemable share issue 9.4% per annum For personal use only Dividend AFT may determine at its absolute discretion whether
Slide 11: Summary Balance Sheet
SUMMARY BALANCE SHEET Restated Unaudited as at 30 Restated Unaudited as at 30 NZ$000's Sep 2016 Sep 2015 For personal use only ASSETS Current assets • AFT had $7.6m cash as Inventories 21,451 15,072 at 28 February 2017, Trade and other receivables 12,748 12,224 Cash and other equivalents 16,054 10,0
AFT Pharmaceuticals — Investor Presentation (March 2017) on 6ix